ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

Summary

This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjects with Type 2 diabetes mellitus. Glycemic control will be measured during a 6-month treatment period in subjects who are on 1 or no antidiabetic drugs

Timeline

Start

2007-08

Primary completion

2008-06

Completion

2008-09

Drugs

Indications